secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cingulate Inc. (CING)
CIK:        0001862150
Form:       8-K
Filed at:   2025-04-09T23:59:59+00:00
Accession:  0001641172-25-003329
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cingulate receives $3M grant from private foundation to accelerate CTx-2103 (buspirone) development
--------------------------------------------------------------------------------

- Grant of $3M in three $1M tranches; first payment May 1, 2025, others upon formulation and development milestones.
- Non-dilutive funding; contingent royalty of $500K per quarter after first commercial sale, max cumulative $3.5M.
- CTx-2103 (buspirone) potential first once-daily formulation for anxiety; U.S. market $5.5B, global $11.6B.
- Grant expands pipeline and validates Cingulate's proprietary Precision Timed Release drug delivery platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1862150/000164117225003329/0001641172-25-003329-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1862150/000164117225003329/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-003329

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer